Patrick E Costantino, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4 College Park Ln, Georgetown, DE 19947 Phone: 302-854-9464 |
Ann Marie Mongeluzo, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 40 Georgetown Plz, Georgetown, DE 19947 Phone: 302-856-2015 |
Mr. Andrea Meyer Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4 Haven Dr, Georgetown, DE 19947 Phone: 302-745-8823 |
Lakshmi Veerareddy, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 432 E Market St, Georgetown, DE 19947 Phone: 302-856-2828 |
Dr. Brooke Lester Darmstadter, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 26351 Patriots Way, 102 Lloyd Lane, Georgetown, DE 19947 Phone: 302-933-3420 Fax: 302-933-3421 |
Gillian Ndi, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2 College Park Ln, Georgetown, DE 19947 Phone: 302-854-5200 |
David Dowling Pharmacist - Pharmacotherapy Medicare: Not Enrolled in Medicare Practice Location: 2 College Park Ln, Georgetown, DE 19947 Phone: 302-853-5200 |
News Archive
Previous studies have shown a link between low vitamin D status and heart disease. Now a new study shows that patients with high blood pressure who possess a gene variant that affects an enzyme critical to normal vitamin D activation are twice as likely as those without the variant to have congestive heart failure.
While the study does not look at the effectiveness of these treatments, "what's concerning is that young people across the country have different levels of access to alternative therapies as publicly-funded services," says Dr. McColl. "There are noticeable differences in access and utilization based on education, income and geographic location."
Sometimes proteins misfold. When that happens in the human brain, the pileup of misfolded proteins can lead to neurodegenerative diseases like Alzheimer's, Parkinson's and ALS.
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary SpiegelmerĀ® technology, today announced successful completion of the first phase I trial with its anti-inflammatory SpiegelmerĀ® NOX-E36. This drug candidate will be developed for the treatment of complications of type 2 diabetes, preferentially diabetic nephropathy, but also others.
The University of Indianapolis will break ground June 19 on a four-story, $28 million Health Pavilion that will house UIndy's healthcare- and wellness-related academic programs as well as industry partners and clinical facilities to serve the community.
› Verified 1 days ago